Moreover, in animal models of NAFLD, SGLT2i inhibits hepatic SGLT2 and reduces serum ALT levels through an upregulation of autophagy via the AMP-activated protein kinase-mammalian target of rapamycin pathway in hepatocytes [33, 34]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.